CN101011607A - Developing polylactic acid microsphere blood vessel suppository - Google Patents
Developing polylactic acid microsphere blood vessel suppository Download PDFInfo
- Publication number
- CN101011607A CN101011607A CN 200710026270 CN200710026270A CN101011607A CN 101011607 A CN101011607 A CN 101011607A CN 200710026270 CN200710026270 CN 200710026270 CN 200710026270 A CN200710026270 A CN 200710026270A CN 101011607 A CN101011607 A CN 101011607A
- Authority
- CN
- China
- Prior art keywords
- polylactic acid
- developing
- blood vessel
- suppository
- acid microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to a developing polylactic acid micro ball vessel suppository, formed by a biological degradable material in polylactic acid and a developing material and baffle the X-ray, wherein, the biological degradable material coats the developing material to form particle structure. The invention has adjustable degrade time; it has better view property in X-ray to support watching plug part; and after plugging, the nuclear magnetic resonance (MRI) can be process; and the invention can suspend in blood, to approach the end blood vessel along with blood, to deposit and plug the vessel; and the diameter of micro ball can be controlled. The invention has low cost.
Description
Technical field
The present invention relates to a kind of vascular suppository material, particularly developing polylactic acid microsphere blood vessel suppository.
Background technology
In the prior art, multiple intervention vascular suppository material has been arranged, mainly contain polyvinyl alcohol (Polyvinyl Alcohol, PVA) microsphere, sodium alginate micro ball, gelfoam, surgical thread, stainless steel spring circle, platinum microcoils, taking off property sacculus, alpha-cyanoacrylate (Cyanoacrylates), dewatered ethanol, iodized oil, sodium morrhuate etc.At clinical use medi-spring steel ring, surgical thread, gelfoam good clinical effectiveness is arranged when bolt blocks up trunk, influence long-term efficacy but prop up circulation foundation because of side.The mistake bolt easily takes place in liquid suppository such as alpha-cyanoacrylate (Cyanoacrylates), dewatered ethanol, iodized oil, sodium morrhuate when clinical manipulation, operation easier is big.Polyvinyl alcohol (Polyvinyl Alcohol, PVA), sodium alginate micro ball and gelfoam, surgical thread etc. be invisible under X-ray, is difficult to observe the thromboembolism position.
The objective of the invention is to provide a kind of comparatively ideal intervention vascular suppository material, particularly end vascular occlusive agent or end vascular suppository material slightly slightly, have the following advantages: X-ray is visual down good, is convenient to observe the thromboembolism position, has avoided the mistake bolt effectively; Have biodegradability, embolus can be degraded in the time of setting, and prevents the excessive damage to organ; Nonferromagnetic can be carried out nuclear magnetic resonance, NMR (MRI) inspection behind the thromboembolism; Proportion is moderate, can suspend in blood, can be convenient to deposition, thromboembolism in blood vessel to end blood vessel drift slightly with the mobile of blood, is difficult for backflowing, and polarization is good; Diameter of micro ball can be controlled; Product price is cheap.
Summary of the invention
The present invention is intended to develop developing polylactic acid microsphere blood vessel suppository, have visual under biodegradability, the X ray, can flowing with blood to advantages such as end blood vessel drift slightly, low prices.
The object of the present invention is achieved like this:
Developing polylactic acid microsphere blood vessel suppository is characterized in that: described developing polylactic acid microsphere blood vessel suppository is made up of polylactic acid-based biodegradation material and roentgenopaque developing material, and biodegradation material parcel developing material forms grain structure.
Described biodegradation material refers to: polylactic acid, poly (lactic acid-glycolic acid) copolymer, the blend or derivatives thereof of polylactic acid-copolyether or above various materials.
Described developing material includes effective development composition of intravascular contrast media.
Further, effective development composition of described intravascular contrast media comprises a kind of in the following material at least: the surplus materials after the ionic contrast agent cardiografin is handled through vacuum freeze-drying method; Surplus materials after non-ionic contrast agent iohexol (Iohexol) or Iopromide (Iopromide) or B-15000 (Iopamidol) are handled through vacuum freeze-drying method; Surplus materials after nonionic dimer iotrolan intravascular contrast media such as (Iotrolan) is handled through vacuum freeze-drying method.
The proportion of described developing polylactic acid microsphere blood vessel suppository is at 0.8g/cm
3To 1.65g/cm
3Between, its optimum is 1.0g/cm
3To 1.35g/cm
3
The diameter of described a kind of pastille developable biodegradable microspheric is between 10 μ m to 1500 μ m, size according to diameter of micro ball is divided into different brackets, 10 μ m～150 μ m, 100 μ m～350 μ m, 200 μ m～500 μ m, 400 μ m～650 μ m, 500 μ m～750 μ m, 650 μ m～950 μ m, 850 μ m～1 100 μ m, 1000 μ m～1350 μ m, 1250 μ m～1500 μ m; With convenient clinical needs.
The present invention's developing polylactic acid microsphere blood vessel suppository, owing to adopted the biodegradation material that in blood vessel, to implant to wrap up the structure that roentgenopaque developing material forms the graininess microsphere, have the following advantages: X-ray is visual down good, be convenient to observe the thromboembolism position, avoided the mistake bolt effectively; Have biodegradability, embolus can be degraded in the time of setting, and prevents the excessive damage to organ; Nonferromagnetic can be carried out nuclear magnetic resonance, NMR (MRI) inspection behind the thromboembolism; Proportion is moderate, can suspend in blood, can be convenient to deposition, thromboembolism in blood vessel to end blood vessel drift slightly with the mobile of blood, is difficult for backflowing, and polarization is good; Diameter of micro ball can be controlled; Product price is cheap; A kind of comparatively ideal intervention vascular suppository material, particularly end vascular suppository material slightly is provided.
Description of drawings
Fig. 1 is the structural representation of the present invention's developing polylactic acid microsphere blood vessel suppository.
Among the above-mentioned figure: 1 is biodegradation material, and 2 is developing material.
Specific embodiment
Embodiment 1: the present invention's development polylactic acid (PLA) microsphere
Buy intravascular contrast media on the market,, after handling through vacuum freeze-drying method, keep the surplus materials after its lyophilization, as developing material (2) as ionic contrast agent cardiografin (Urografin).
Adopt polylactic acid as biodegradation material (1), can make developing material (2) microsphere easily according to the common processes that polylactic acid is made the pastille microsphere as the lapping of medicine.
Polylactic acid is made the pastille microsphere as the lapping of various medicines, and many common processes have been arranged.As: set sail etc. and on " China Medicine University's journal,, 35 (3): 207-210 in 2004 ", to have delivered " ciprofloxacin polylactic acid microsphere preparation technology's research ", disclose a kind of preparation technology who contains the lactic acid microspheres of ciprofloxacin medicine in the article; Zhao Ruiling has delivered the article of " preparation of amycin polylactic acid microsphere and release behaviour in vitro research " on " the 24th the 2nd phase of volume of Chinese Hospitals pharmaceutical journal 2004 ", disclose a kind of preparation technology who contains the lactic acid microspheres of amycin medicine in the article; Li Yan etc. have delivered " preparation of polylactic acid, poly (lactic acid-glycolic acid) copolymer microsphere and influence the progress of its qualitative factor " review article on " foreign medical science pharmacy fascicle; June calendar year 2001; the 28th the 3rd phase of volume ", disclose the preparation of various microspheres in the article and influenced the factor of microspheres quality.
The manufacturing of the present invention's product can adopt emulsifying-solvent evaporated method preparation to contain the polylactic acid microsphere of developing material (2), and specific practice is as follows:
An amount of polylactic acid is dissolved in the organic solvent (as dichloromethane), and a certain proportion of developing material (2) is scattered in wherein, under certain mixing speed, slowly be added in the disperse medium (PVA solution), behind the emulsifying certain hour, be poured into volatilization organic solvent in the dispersive medium (low concentration PVA solution) again, centrifugal then, filter, clean, dry, screening, sterilization, promptly get the polylactic acid microsphere that contains developing material (2).
In the present embodiment, developing material (2) can also adopt the surplus materials after non-ionic contrast agent iohexol (Iohexol) or Iopromide (Iopromide) or B-15000 (Iopamidol), nonionic dimer iotrolan intravascular contrast media such as (Iotrolan) are handled through vacuum freeze-drying method.Adopt essentially identical technology also can make the present invention's roentgenopaque Biodegradable vascular suppository material.
Embodiment 2: the present invention's development poly (lactic acid-glycolic acid) copolymer (PLGA) microsphere
The production method of present embodiment product is substantially the same manner as Example 1, difference is biodegradation material (1) is chosen as the poly (lactic acid-glycolic acid) copolymer, and developing material (2) can be selected from a kind of in the following material: the surplus materials after the ionic contrast agent cardiografin is handled through vacuum freeze-drying method; Surplus materials after non-ionic contrast agent iohexol (iohexol) or Iopromide (iopromide) or B-15000 (iopamidol) are handled through vacuum freeze-drying method; Surplus materials after nonionic dimer iotrolan intravascular contrast media such as (iotrolan) is handled through vacuum freeze-drying method.
The present invention's most of development PLA and development PLGA microsphere all adopt the emulsifying dispersion method and are separated the coacervation preparation.In addition, can also adopt supercritical flow new, the solution atomization that will comprise biodegradation material (1) and developing material (2) sprays into and contains compression CO
2Container in because organic solvent is at CO
2In extraction and diffusion cause polymer precipitation and prepared development biodegradation material microspheres such as development PLA, development PLGA, the microsphere flowability, the outward appearance that obtain are all better, and have reduced dosage of surfactant and residual solvent amount.
Embodiment 3: development polylactic acid-copolyether microsphere of the present invention
The production method of present embodiment product is substantially the same manner as Example 1, difference is biodegradation material (1) is chosen as polylactic acid-copolyether, and developing material (2) can be selected from a kind of in the following material: the surplus materials after the ionic contrast agent cardiografin is handled through vacuum freeze-drying method; Surplus materials after non-ionic contrast agent iohexol (iohexol) or Iopromide (iopromide) or B-15000 (iopamidol) are handled through vacuum freeze-drying method; Surplus materials after nonionic dimer iotrolan intravascular contrast media such as (iotrolan) is handled through vacuum freeze-drying method.Adopt the general emulsifying dispersion method and the coacervation that is separated to prepare microsphere or CO
2Supercritical flow new prepares microsphere.
In addition, molecular weight that can be by regulating biodegradation material (1) and the chemical group method of grading, the degradation time of control the present invention's development microsphere, convenient clinical needs, as: the microsphere of degraded in 7 days, the microsphere of degraded in 15 days, the microsphere of degraded in 30 days, the microsphere of degraded in 60 days, the microsphere of degraded in 180 days etc.
Should be noted that herein openly can replace with the identical structure of other effect that the embodiment that the present invention introduced simultaneously realizes unique structure of the present invention with the structure of explanation.Though preferential embodiment of the present invention is introduced in this article and is illustrated; but those skilled in the art know and know that these embodiment illustrate; those skilled in the art can make countless variations, improvement and replacement; and can not break away from the present invention; therefore, should be according to the next qualification protection scope of the present invention of the spirit and scope of appending claims of the present invention.
Claims (6)
1, developing polylactic acid microsphere blood vessel suppository, it is characterized in that: described developing polylactic acid microsphere blood vessel suppository is made up of polylactic acid-based biodegradation material (1) and roentgenopaque developing material (2), and biodegradation material (1) parcel developing material (2) forms grain structure.
2, developing polylactic acid microsphere blood vessel suppository according to claim 1, it is characterized in that described biodegradation material (1) refers to: polylactic acid, the poly (lactic acid-glycolic acid) copolymer, the blend or derivatives thereof of polylactic acid-copolyether or above various materials.
3, developing polylactic acid microsphere blood vessel suppository according to claim 1 is characterized in that described developing material (2) includes effective development composition of intravascular contrast media.
4, developing polylactic acid microsphere blood vessel suppository according to claim 3, the effective development composition that it is characterized in that described intravascular contrast media comprise a kind of in the following material at least: the surplus materials after the ionic contrast agent cardiografin is handled through vacuum freeze-drying method; Surplus materials after non-ionic contrast agent iohexol (Iohexol) or Iopromide (Iopromide) or B-15000 (Iopamidol) are handled through vacuum freeze-drying method; Surplus materials after nonionic dimer iotrolan (Iotrolan) is handled through vacuum freeze-drying method.
5, developing polylactic acid microsphere blood vessel suppository according to claim 1, the proportion that it is characterized in that described developing polylactic acid microsphere blood vessel suppository is at 0.8g/cm
3To 1.65g/cm
3Between, its optimum is 1.0g/cm
3To 1.35g/cm
3
6, according to the described developing polylactic acid microsphere blood vessel suppository of claim 1, the diameter that it is characterized in that described a kind of pastille developable biodegradable microspheric is between 10 μ m to 1500 μ m, according to the size of diameter of micro ball, be divided into different brackets, 10 μ m～150 μ m, 100 μ m～350 μ m, 200 μ m～500 μ m, 400 μ m～650 μ m, 500 μ m～750 μ m, 650 μ m～950 μ m, 850 μ m～1100 μ m, 1000 μ m～1350 μ m, 1250 μ m～1500 μ m.
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710026270 CN101011607A (en) | 2007-01-12 | 2007-01-12 | Developing polylactic acid microsphere blood vessel suppository |
| PCT/CN2008/070100 WO2008086756A1 (en) | 2007-01-12 | 2008-01-14 | Developable biodegradable microspheric blood vessel embolism materials |
| BRPI0807024-5A BRPI0807024A2 (en) | 2007-01-12 | 2008-01-14 | Biodegradable and radiopaque microspheric material for vascular embulism |
| EP08700770A EP2105150A1 (en) | 2007-01-12 | 2008-01-14 | Developable biodegradable microspheric blood vessel embolism materials |
| JP2009545051A JP2010515493A (en) | 2007-01-12 | 2008-01-14 | Radiopaque biodegradable microsphere type vascular embolization material |
| US12/523,046 US20100021550A1 (en) | 2007-01-12 | 2008-01-14 | Radiopaque biodegradable vascular embolic microspheres |
| CN200880002136A CN101652151A (en) | 2007-01-12 | 2008-01-14 | Biodegradable imaging microspheres vascular embolization material |
| IL199805A IL199805A0 (en) | 2007-01-12 | 2009-07-12 | Developable biodegradable microspheric blood vessel embolism materials |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710026270 CN101011607A (en) | 2007-01-12 | 2007-01-12 | Developing polylactic acid microsphere blood vessel suppository |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101011607A true CN101011607A (en) | 2007-08-08 |
Family
ID=38699441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710026270 Pending CN101011607A (en) | 2007-01-12 | 2007-01-12 | Developing polylactic acid microsphere blood vessel suppository |
| CN200880002136A Pending CN101652151A (en) | 2007-01-12 | 2008-01-14 | Biodegradable imaging microspheres vascular embolization material |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880002136A Pending CN101652151A (en) | 2007-01-12 | 2008-01-14 | Biodegradable imaging microspheres vascular embolization material |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN101011607A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008086756A1 (en) * | 2007-01-12 | 2008-07-24 | Yanfang Li | Developable biodegradable microspheric blood vessel embolism materials |
| CN102107025A (en) * | 2010-08-27 | 2011-06-29 | 微创医疗器械(上海)有限公司 | Embolic material composite and preparation method thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106913383B (en) * | 2015-12-25 | 2020-04-21 | 先健科技(深圳)有限公司 | Developing structure and implantable medical device with same |
| DE102020101197A1 (en) * | 2020-01-20 | 2021-07-22 | Charité - Universitätsmedizin Berlin | Medical device for drug delivery with enhanced effect |
| CN113663119A (en) * | 2021-07-07 | 2021-11-19 | 核工业总医院 | Preparation method of iodized oil silk fibroin embolism microsphere with perspective developing function |
| CN115400266B (en) * | 2022-09-05 | 2024-01-19 | 北京邦塞科技有限公司 | Composite microsphere, bone cement and preparation method and application thereof |
-
2007
- 2007-01-12 CN CN 200710026270 patent/CN101011607A/en active Pending
-
2008
- 2008-01-14 CN CN200880002136A patent/CN101652151A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008086756A1 (en) * | 2007-01-12 | 2008-07-24 | Yanfang Li | Developable biodegradable microspheric blood vessel embolism materials |
| CN102107025A (en) * | 2010-08-27 | 2011-06-29 | 微创医疗器械(上海)有限公司 | Embolic material composite and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101652151A (en) | 2010-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101007189A (en) | Biodegradable imaging microspheres vascular embolization material containing drug | |
| CN101007190A (en) | Biodegradable imaging microspheres vascular embolization material | |
| Wongkanya et al. | Electrospinning of alginate/soy protein isolated nanofibers and their release characteristics for biomedical applications | |
| CN101011607A (en) | Developing polylactic acid microsphere blood vessel suppository | |
| Chen et al. | Preparation of chitosan/nano hydroxyapatite organic–inorganic hybrid microspheres for bone repair | |
| US10463619B2 (en) | Injectable delivery of microparticles and compositions therefor | |
| CN1953803B (en) | Method for preparing calibrated biodegradable microspheres | |
| Chen et al. | Natural polysaccharide based complex drug delivery system from microfluidic electrospray for wound healing | |
| WO2008086756A1 (en) | Developable biodegradable microspheric blood vessel embolism materials | |
| Yang et al. | Electrospun micelles/drug‐loaded nanofibers for time‐programmed multi‐agent release | |
| Abdul Hameed et al. | Core-shell nanofibers from poly (vinyl alcohol) based biopolymers using emulsion electrospinning as drug delivery system for cephalexin drug | |
| CN103599090A (en) | Multi-layer drug sustain-release nano fiber membrane and preparation method thereof | |
| CN101283025B (en) | Biodegradable particle and method for producing the same | |
| CN104271171A (en) | Injectable biodegradable particles for controlled therapeutic agent release | |
| CN101011608A (en) | Developing polylactic acid microsphere blood vessel suppository containing antitumor agent | |
| CN104225614A (en) | Chitosan grafted polylactic acid composite microsphere simultaneously carried with hydrophilic and hydrophobic biological molecules and preparation method of chitosan grafted polylactic acid composite microsphere | |
| WO2023046998A1 (en) | Fibers electrospinning including microfluidics method | |
| Geiger et al. | Dual drug release from CO2‐infused nanofibers via hydrophobic and hydrophilic interactions | |
| Hawkins et al. | Physicomechanical properties and in vitro release behaviors of electrospun ibuprofen-loaded blend PEO/EC fibers | |
| CN201055537Y (en) | Developing polylactic acid microspheric vascellum suppository | |
| WO2005061095A1 (en) | Process for producing microsphere and apparatus for producing the same | |
| Han et al. | Diverse release behaviors of water-soluble bioactive substances from fibrous membranes prepared by emulsion and suspension electrospinning | |
| Liu et al. | Self-assembly behavior and doxorubicin-loading capacity of acylated carboxymethyl chitosans | |
| CN201058140Y (en) | Developing polylactic acid series microspheric vascellum suppository containing antineoplastic medicine | |
| CN201055538Y (en) | Biological degradation developing microspheric vascellum embolism material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20070808 |